Stock Research for OPHT

OPHT

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

OPHT Stock Chart & Research Data

The OPHT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the OPHT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


OPHT Due diligence Resources & Stock Charts

The OPHT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View OPHT Detailed Price Forecast - CNN Money CNN View OPHT Detailed Summary - Google Finance
Yahoo View OPHT Detailed Summary - Yahoo! Finance Zacks View OPHT Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View OPHT Trends & Analysis - Trade-Ideas Barrons View OPHT Major Holders - Barrons
NASDAQ View OPHT Call Transcripts - NASDAQ Seeking View OPHT Breaking News & Analysis - Seeking Alpha
Spotlight View OPHT Annual Report - CompanySpotlight.com OTC Report View OPHT OTC Short Report - OTCShortReport.com
TradeKing View OPHT Fundamentals - TradeKing Charts View OPHT SEC Filings - Bar Chart
WSJ View Historical Prices for OPHT - The WSJ Morningstar View Performance/Total Return for OPHT - Morningstar
MarketWatch View the Analyst Estimates for OPHT - MarketWatch CNBC View the Earnings History for OPHT - CNBC
StockMarketWatch View the OPHT Earnings - StockMarketWatch MacroAxis View OPHT Buy or Sell Recommendations - MacroAxis
Bullish View the OPHT Bullish Patterns - American Bulls Short Pains View OPHT Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View OPHT Stock Mentions - StockTwits PennyStocks View OPHT Stock Mentions - PennyStockTweets
Twitter View OPHT Stock Mentions - Twitter Invest Hub View OPHT Investment Forum News - Investor Hub
Yahoo View OPHT Stock Mentions - Yahoo! Message Board Seeking Alpha View OPHT Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for OPHT - SECform4.com Insider Cow View Insider Transactions for OPHT - Insider Cow
CNBC View OPHT Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for OPHT - OTC Markets
Yahoo View Insider Transactions for OPHT - Yahoo! Finance NASDAQ View Institutional Holdings for OPHT - NASDAQ


Stock Charts

FinViz View OPHT Stock Insight & Charts - FinViz.com StockCharts View OPHT Investment Charts - StockCharts.com
BarChart View OPHT Stock Overview & Charts - BarChart Trading View View OPHT User Generated Charts - Trading View


Latest Financial News for OPHT

electroCore, Inc. Announces Additions to Board of Directors in Connection with Recently Completed Initial Public Offering
Posted on Tuesday July 10, 2018

BASKING RIDGE, N.J., July 10, 2018-- electroCore, Inc., a commercial-stage bioelectronic medicine company, today announced the appointment of Carrie S. Cox as Chairman of its Board of Directors, and Michael ...


Ophthotech (OPHT) Soars: Stock Adds 10.4% in Session
Posted on Friday June 08, 2018

Ophthotech (OPHT) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.


Today’s Research Reports on Stocks to Watch: Proteostasis Therapeutics and Ophthotech Corporation
Posted on Friday June 08, 2018

NEW YORK, NY / ACCESSWIRE / June 8, 2018 / While Proteostasis Therapeutics announced positive results from an ongoing 14-day dosing study of PTI-801, an analyst at RBC Capital Markets didn't seem impressed and downgraded the company this week as well as lowered his price target on shares. Ophthotech Corporation saw a different story yesterday, gaining over 10% after announcing that it has entered into an exclusive global license agreement with the University of Florida Research Foundation and the University of Pennsylvania. The results had shown statistically significant improvement in sweat chloride, body mass index, and weight and blood glucose.


Ophthotech Enters into Gene Therapy Agreements with the University of Florida and the University of Pennsylvania
Posted on Thursday June 07, 2018

Ophthotech Corporation (OPHT) announced today that it has entered into an exclusive global license agreement with the University of Florida Research Foundation and the University of Pennsylvania (Penn) to develop and commercialize a novel adeno-associated virus (AAV) gene therapy product for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP), an orphan monogenic disease that is characterized by progressive and severe loss of vision leading to blindness. Preclinical anatomical and functional proof-of-concept studies have demonstrated promising results in a canine disease model. In addition to the exclusive license agreement, Ophthotech and Penn have also entered into a master sponsored research agreement, facilitated by the Penn Center for Innovation (PCI), pursuant to which Ophthotech and Penn plan to conduct preclinical and natural history studies.


Enter a stock symbol to view the stock details.